Can glucose metabolic heterogeneity signal prognosis in non-small cell lung cancer (NSCLC) patients treated with erlotinib?

Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.

A new cohort study shows that some immune-related adverse events are linked to longer survival in patients with NSCLC treated with immunotherapy.

The spotlight was on EGFR+ NSCLC at ASCO 2025, as Drs Olazagasti, Velez, and Velázquez Mañana discuss the latest trial findings.

The antibody-drug conjugate is approved for previously treated advanced NSCLC patients with high c-Met protein overexpression.

In a real-world population of patients with EGFR-mutant advanced lung cancer, overall survival was much worse in patients who would not have been eligible for the pivotal FLAURA trial.

Lung Cancer : Review in-depth clinical information, latest medical news, and guidelines on lung cancer, specifically small-cell lung cancer and non-small-cell lung cancer. Read the latest ...

Patients with advanced NSCLC who received optimal first-line treatment based on biomarker testing demonstrated better outcomes, new findings showed.

The new approval is durvalumab's first indication for resectable NSCLC. The agent has been previously approved for unresectable or metastatic disease as well as extensive-stage small …

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.